A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2

Accepted/In Press date: 25 July 2023

e-pub ahead of print date: 2 October 2023

Additional Information: Funding Information: The study protocol was reviewed and approved by the UK Medicines and Healthcare Products Regulatory Agency (EudraCT: 2020-001736-95; registered 28 April 2020). Ethical approval was received from the relevant Health Research Authority and Research Ethics Committee. An independent data monitoring committee assessed safety throughout the study. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, Council for International Organizations of Medical Sciences International Ethical Guidelines, International Council for Harmonisation (ICH) Good Clinical Practice Guidelines, and applicable local laws and regulations. The ACCORD-2 study was sponsored by University Hospital Southampton NHS Foundation Trust, and was funded by UK Research and Innovation. Funding Information: Acknowledgements: Medical writing support was provided by Charlie Foster and Sinéad Flannery (PharmaGenesis London, London, UK), with funding from AstraZeneca. The authors thank Helen Killick (AstraZeneca, Cambridge, UK) for scientific and operational support. The authors also thank Martin Wiselka (University Hospitals of Leicester NHS Trust, Leicester, UK), Stephen Ryder (Nottingham University Hospitals NHS Trust, Nottingham, UK ), Niranjan Setty (Basildon & Thurrock University Hospitals NHS Foundation Trust, Basildon, UK) and Nuria Martinez-Alier (Evelina London Children’s Hospital, Guy’s and St Thomas Hospital NHS Foundation Trust, London, UK), and the participants, investigators and all staff involved in the study. The authors acknowledge the support of the Medicines Evaluation Unit, Manchester, IQVIA, National Institute for Health and Care Research (NIHR) Respiratory Translational Research Collaboration, NIHR Southampton, Biomedical Research Centre and the NIHR Clinical Research Facilities in Manchester. Publisher Copyright: © The authors 2023.

Local EPrints ID: 485590

URI: http://eprints.soton.ac.uk/id/eprint/485590

DOI: doi:10.1183/23120541.00249-2023

ISSN: 2312-0541

PURE UUID: f487c6e5-3eca-4029-bd60-fa48734f838a

ORCID for Gareth Griffiths: orcid.org/0000-0002-9579-8021

Date deposited: 12 Dec 2023 17:30

Last modified: 18 Mar 2024 03:30